East and North Hertfordshire NHS Trust is proud to have played a part in a drugs trial which improves survival rates in hospitalised patients with respiratory problems.
We had 24 patients take part in the UK-wide trial called RECOVERY – Randomised Evaluation of COVid-19 thERapY – which found that steroid dexamethasone reduced the risk of dying by one third in ventilated patients and by one fifth in other patients receiving oxygen only. There was no benefit among those who did not need respiratory intervention.
Phillip Smith, Associate Director for Research and Development at East and North Hertfordshire NHS Trust, said: “We are very proud to have played a part in this trial, which hopefully will lead to fewer families losing loved ones to COVID-19.
“A huge thank you to the patients who took part and to everyone within the trust who has made this happen. It has been a real team effort.”
More information about the trial can be found here: https://www.nihr.ac.uk/news/first-drug-to-reduce-mortality-in-hospitalised-patients-with-respiratory-complications-of-covid-19-found/25061
